89 related articles for article (PubMed ID: 21491734)
1. [Inflammation and lipids in the coronary pathology. Risk factors, causes or therapeutic target?].
Filardi PP; Cecere M; Savarese G; Damore C; Parente A; Conte S; Coutsoumbas G
G Ital Cardiol (Rome); 2010 Dec; 11(12 Suppl 3):10S-15S. PubMed ID: 21491734
[TBL] [Abstract][Full Text] [Related]
2. Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER)--can C-reactive protein be used to target statin therapy in primary prevention?
Mora S; Ridker PM
Am J Cardiol; 2006 Jan; 97(2A):33A-41A. PubMed ID: 16442935
[TBL] [Abstract][Full Text] [Related]
3. Number needed to treat with rosuvastatin to prevent first cardiovascular events and death among men and women with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin (JUPITER).
Ridker PM; MacFadyen JG; Fonseca FA; Genest J; Gotto AM; Kastelein JJ; Koenig W; Libby P; Lorenzatti AJ; Nordestgaard BG; Shepherd J; Willerson JT; Glynn RJ;
Circ Cardiovasc Qual Outcomes; 2009 Nov; 2(6):616-23. PubMed ID: 20031900
[TBL] [Abstract][Full Text] [Related]
4. The Jupiter study, CRP screening, and aggressive statin therapy-implications for the primary prevention of cardiovascular disease.
Kones R
Ther Adv Cardiovasc Dis; 2009 Aug; 3(4):309-15. PubMed ID: 19460829
[TBL] [Abstract][Full Text] [Related]
5. Rosuvastatin: a review of its use in the prevention of cardiovascular disease in apparently healthy women or men with normal LDL-C levels and elevated hsCRP levels.
Carter NJ
Am J Cardiovasc Drugs; 2010; 10(6):383-400. PubMed ID: 21090831
[TBL] [Abstract][Full Text] [Related]
6. Predicting benefit from statins by C-reactive protein, LDL-cholesterol or absolute cardiovascular risk.
Stewart RA
Future Cardiol; 2009 May; 5(3):231-6. PubMed ID: 19656039
[TBL] [Abstract][Full Text] [Related]
7. Primary prevention of vascular events in patients with high levels of C-reactive protein: the JUPITER study.
Fonseca FA; Izar MC
Expert Rev Cardiovasc Ther; 2009 Sep; 7(9):1041-56. PubMed ID: 19764857
[TBL] [Abstract][Full Text] [Related]
8. Baseline characteristics of participants in the JUPITER trial, a randomized placebo-controlled primary prevention trial of statin therapy among individuals with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein.
Ridker PM; Fonseca FA; Genest J; Gotto AM; Kastelein JJ; Khurmi NS; Koenig W; Libby P; Lorenzatti AJ; Nordestgaard BG; Shepherd J; Willerson JT; Glynn RJ;
Am J Cardiol; 2007 Dec; 100(11):1659-64. PubMed ID: 18036365
[TBL] [Abstract][Full Text] [Related]
9. The JUPITER trial: How will it change clinical practice?
Watson KE
Rev Cardiovasc Med; 2009; 10(2):91-6. PubMed ID: 19593321
[TBL] [Abstract][Full Text] [Related]
10. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women.
Ridker PM; Hennekens CH; Buring JE; Rifai N
N Engl J Med; 2000 Mar; 342(12):836-43. PubMed ID: 10733371
[TBL] [Abstract][Full Text] [Related]
11. [The JUPITER study: critical review of final results].
Urbinati S; Romanazzi S; Gambetti S
G Ital Cardiol (Rome); 2009 Dec; 10(11-12 Suppl 3):28S-32S. PubMed ID: 21298859
[TBL] [Abstract][Full Text] [Related]
12. Relationship between baseline inflammatory markers, antiplatelet therapy, and adverse cardiac events after percutaneous coronary intervention: an analysis from the clopidogrel for the reduction of events during observation trial.
Dosh K; Berger PB; Marso S; van Lente F; Brennan DM; Charnigo R; Topol EJ; Steinhubl S
Circ Cardiovasc Interv; 2009 Dec; 2(6):503-12. PubMed ID: 20031767
[TBL] [Abstract][Full Text] [Related]
13. C-reactive protein is not only an inflammatory marker but also a direct cause of cardiovascular diseases.
Li JJ; Fang CH
Med Hypotheses; 2004; 62(4):499-506. PubMed ID: 15050096
[TBL] [Abstract][Full Text] [Related]
14. Coronary artery disease prognosis and C-reactive protein levels improve in proportion to percent lowering of low-density lipoprotein.
O'Keefe JH; Cordain L; Jones PG; Abuissa H
Am J Cardiol; 2006 Jul; 98(1):135-9. PubMed ID: 16784936
[TBL] [Abstract][Full Text] [Related]
15. The effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity and cardiovascular biomarkers in patients with stable coronary heart disease or coronary heart disease risk equivalent: the results of a multicenter, randomized, double-blind, placebo-controlled study.
Mohler ER; Ballantyne CM; Davidson MH; Hanefeld M; Ruilope LM; Johnson JL; Zalewski A;
J Am Coll Cardiol; 2008 Apr; 51(17):1632-41. PubMed ID: 18436114
[TBL] [Abstract][Full Text] [Related]
16. Cardiovascular risk reduction: what do recent trials with rosuvastatin tell us?
Fabbri G; Maggioni AP
Adv Ther; 2009 May; 26(5):469-87. PubMed ID: 19444394
[TBL] [Abstract][Full Text] [Related]
17. Relation of baseline high-sensitivity C-reactive protein level to cardiovascular outcomes with rosuvastatin in the Justification for Use of statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER).
Ridker PM; MacFadyen J; Libby P; Glynn RJ
Am J Cardiol; 2010 Jul; 106(2):204-9. PubMed ID: 20599004
[TBL] [Abstract][Full Text] [Related]
18. [Inflammation and C-reactive protein in cardiovascular disease].
Munk PS; Larsen AI
Tidsskr Nor Laegeforen; 2009 Jun; 129(12):1221-4. PubMed ID: 19521445
[TBL] [Abstract][Full Text] [Related]
19. [The JUPITER study: background and research hypotheses].
Rapezzi C; Gallo P
G Ital Cardiol (Rome); 2009 Dec; 10(11-12 Suppl 3):25S-27S. PubMed ID: 21298858
[TBL] [Abstract][Full Text] [Related]
20. C-reactive protein: risk assessment in the primary prevention of atherosclerotic disease. Has the time come for including it in the risk profile?
Koenig W
Ital Heart J; 2001 Mar; 2(3):157-63. PubMed ID: 11305526
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
